Oncopeptides AB
Oncopeptides AB is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Oncopeptides AB.
Oncopeptides AB is a company.
Key people at Oncopeptides AB.
Key people at Oncopeptides AB.
Oncopeptides AB (publ) is a Stockholm-based biotechnology company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological cancers, particularly relapsed refractory multiple myeloma.[1][2] Its lead product, Pepaxti (melflufen), a Peptide Drug Conjugate (PDC) approved in Europe, targets adult patients with multiple myeloma by exploiting cancer cells' altered metabolism to deliver cytotoxic payloads selectively.[1][2] The company serves patients with unmet needs in oncology, solving challenges in treating resistant cancers through its PDC and SPiKE platforms, with a pipeline including OPD5, OPDC3, Gliopep for hematological/solid tumors and glioblastoma, and SPiKE for NK-cell engagement.[1][2] With 75-80 employees and headquarters in Stockholm, Oncopeptides demonstrates growth through full European approval of its first drug and ongoing pipeline advancement.[1][2]
Oncopeptides AB was founded in 2000 by Sweden's leading cancer researchers and institutions to develop anti-cancer drugs, starting with melflufen, which gained patent protection that year.[2][3] Early preclinical development (2003-2009) was financed by Industrifonden and Karolinska Development AB, leading to Phase 1 studies in solid tumors at Uppsala University Hospital and a key U.S. collaboration with Harvard Medical School–Dana-Farber Cancer Institute in 2009-2011, including a new freeze-dried formulation.[3] Pivotal investments from 2012-2013 by HealthCap, Industrifonden, and others funded Phase 1/2 trials in multiple myeloma; by 2017, the company went public on Nasdaq Stockholm (ticker: ONCO), launched the Phase 3 OCEAN and Phase 2 HORIZON studies, and secured patents until 2032.[1][3] This evolution from research spinout to commercial-stage biotech humanizes its mission-driven focus on patient access to innovative alkylating drugs after 25 years of development.[2][3]
Oncopeptides stands out in oncology biotech through:
Oncopeptides rides the wave of precision oncology and antibody-drug conjugate (ADC) evolution, where targeted therapies address unmet needs in hematological malignancies amid rising multiple myeloma incidence and resistance to standard treatments like CAR-T and proteasome inhibitors.[1][2] Timing aligns with post-2020 regulatory accelerations for novel conjugates, bolstered by European approval and U.S. pursuits, amid market forces favoring platforms like PDC/SPiKE for their tumor-selective delivery over traditional chemotherapies.[1][3] It influences the ecosystem by validating Swedish biotech innovation, fostering U.S.-Europe collaborations (e.g., Dana-Farber), and contributing to the global shift toward metabolism-exploiting drugs, potentially expanding to solid tumors.[2][3]
Oncopeptides is poised for pipeline expansion with PDC/SPiKE candidates advancing toward clinical readouts, U.S. commercialization of Pepaxti, and potential partnerships leveraging its 2032 patents.[1][3] Trends like AI-accelerated drug design and combination therapies for myeloma will shape its path, amplifying influence if OCEAN/HORIZON data sustain survival benefits.[3] Evolving from a research pioneer to a transformative player, it exemplifies resilient biotech grit in delivering hope through targeted innovation—much like its founding vision amid oncology's toughest challenges.[2]
